Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring System

Leukemia and Lymphoma

Volumn 48, Issue 6, 2007, Pages 1150-1160

  Beran, Miloslav ^a   Wen, Sijin ^b   Shen, Yu ^b   Onida, Francesco ^c,d   Jelinek, Jaroslav ^a   Cortes, Jorge ^a   Giles, Francis ^a   Kantarjian, Hagop ^a  

^a Department of Leukemia ^*  (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d Matarelli Foundation for Blood Diseases   (Italy)

Author keywords

Chronic myelomonocytic leukemia; Risk assessment; Scoring system

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SCORING SYSTEM; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 34347346041     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701216386     Document Type: Article

References (23)

1. Onida, F., Kantarjian, H. M., Smith, T. L., Bell, G., Keating, M. J. and Estey, E. H. (2002) Prognostic factors and scoring systems in chronic myelomonocytic leukemia: A retrospective analysis of 213 patients. Blood, 99, pp. 840-849.
2. Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P. and Sanz, G. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, pp. 2079-2088.
3. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D AG and Gralnick, H. R. (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol, 51, pp. 189-199.
4. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D AG and Gralnick, H. R. (1994) The chronic myeloid leukemias: Guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol, 87, pp. 746-754.
5. Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K. and Vardiman, J. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol, 17, pp. 3835-3849.
6. Themeau, T. M., Grambusch, P. M. and Fleming, T. R. (1990) Martingale-based residuals for survival models. Biometrika, 77, pp. 147-160.
7. Cox, D. R. (1972) Regression models and life tables (with discussion). J Stat Soc, 34, pp. 187-220.
8. Malcovati, L., Della Porta, M. G., Pascutto, C., Invernizzi, R., Boni, M. and Travaglino, E. (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol, 23, pp. 7594-7603.
9. Sokal, J. E. (1987) Prognosis in chronic myeloid leukaemia: Biology of the disease vs. treatment. Baillieres Clin Haematol, 1, pp. 907-929.
10. Onida, F., Ball, G., Kantarjian, H. M., Smith, T. L., Glassman, A. and Albitar, M. (2002) Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer, 95, pp. 1673-1684.
11. Aul, C., Gattermann, N., Heyll, A., Germing, U., Derigs, G. and Schneider, W. (1992) Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia, 6, pp. 52-59.
12. Worsley, A., Oscier, D. G., Stevens, J., Darlow, S., Figes, A. and Mufti, G. J. (1988) Prognostic features of chronic myelomonocytic leukaemia: A modified Bournemouth score gives the best prediction of survival. Br J Haematol, 68, pp. 17-21.
13. Molica, S., Iannaccaro, P. and Albeti, A. (1990) Chronic myelomonocytic leukemia: A test of a proposed staging system. Am J Hematol, 35, pp. 129-130.
14. Solal-Celigny, P., Desaint, B., Herrera, A., Chastang, C., Amar, M. and Vroclans, M. (1984) Chronic myelomonocytic leukemia according to FAB classification: Analysis of 35 cases. Blood, 63, pp. 634-638.
15. Germing, U., Strupp, C., Alvado, M. and Gattermann, N. (2002) New prognostic parameters for chronic myelomonocytic leukemia?. Blood, 100, pp. 731-732.
16. Germing, U., Kundgen, A. and Gattermann, N. (2004) Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma, 45, pp. 1311-1318.
17. Bowen, D. T. (2005) Chronic myelomonocytic leukemia: Lost in classification?. Hematol Oncol, 23, pp. 26-33.
18. Golub, T. R., Barker, G. F., Lowett, M. and Gilleland, D. G. (1994) Fusion of PDGF receptor β to a novel ets-like gene tel in chronic myelomonocytic leukemia with a t(5;12) chromosomal translocation. Cell, 77, pp. 307-316.
19. Gupta, R., Knight, C. L. and Bain, B. J. (2002) Receptor tyrosine kinase mutations in myeloid neoplasms (review). Br J Haematol, 117, pp. 489-508.
20. Pitini, V., Arrigo, C., Teti, D., Barresi, G., Righi, M. and Alo, G. (2003) Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: A new case report. Haematologica, 88, p. ECR18.
21. Levine, R., Loriaux, M., Huntly, B JP, Loh, M. L., Beran, M. and Stoffregen, E. (2005) The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood, 106, pp. 3377-3379.
22. Jelinek, J., Oki, Y., Gharibzan, V., Bueso-Ramos, C., Prchal, J. T. and Verstovsek, S. (2005) JAK2 mutation 1849G
23. Steensma, D. P., Dewald, G. W., Lasha, T. L., Powell, H. L., McClure, R. F. and Lenine, R. L. (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and the myelodysplastic syndromes. Blood, 106, pp. 1207-1209.